

Current Approaches and Future Strategies in Oncology: A Multitumor Educational Symposium in Partnership with Florida Cancer Specialists & Research Institute

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following outcomes was observed with datopotamab deruxtecan among patients with HR-positive, HER2-negative metastatic breast cancer in the Phase III TROPION-Breast01 trial?
 - Primary endpoint for progression-free survival (PFS) was met
 - Primary endpoint for PFS was not met
- What is the approximate PFS benefit observed with alpelisib in combination with endocrine therapy as second-line treatment for patients with HR-positive, HER2-negative metastatic breast cancer with a PIK3CA mutation after disease progression on a CDK4/6 inhibitor?
 - One to 2 months
 - Five to 7 months
 - Eleven to 13 months
- Olaparib in combination with abiraterone acetate and prednisone is an FDA-approved regimen for which patients with metastatic hormone-resistant prostate cancer?
 - Patients with any homologous recombination repair gene mutation
 - Patients with a BRCA mutation
 - Patients with a BRCA2 or PALB2 mutation
 - All patients, independent of homologous recombination repair gene mutations
- What was the approximate reduction in the risk of disease progression or death for patients receiving lutetium Lu 177 vipivotide tetraxetan for PSMA-positive metastatic castration-resistant prostate cancer in the Phase III VISION trial?
 - 10%
 - 20%
 - 40%
 - 60%
- What was the approximate reduction in risk of death with 3 years of adjuvant osimertinib for patients with Stage IB to IIIA non-small cell lung cancer and an EGFR mutation in the Phase III ADAURA trial?
 - No reduction
 - 11%
 - 26%
 - 51%
- Which of the following targeted therapies has demonstrated clinical activity in patients who have experienced disease progression on osimertinib?
 - Amivantamab/lazertinib
 - Patritumab deruxtecan
 - Both a and b
 - None of the above
- What was the approximate response rate observed with the combination regimen tucatinib/trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer in the Phase II MOUNTAINEER trial?
 - 4%
 - 16%
 - 38%
- The anti-PD-1 antibody tislelizumab was engineered to minimize binding to which of the following receptors?
 - BCR on B cells
 - LAG-3 on NK cells
 - FcγR on macrophages
 - TCR on T cells

Current Approaches and Future Strategies in Oncology: A Multitumor Educational Symposium in Partnership with Florida Cancer Specialists & Research Institute

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Which of the following Bruton tyrosine kinase inhibitors binds noncovalently/reversibly?
- a. Acalabrutinib
 - b. Ibrutinib
 - c. Pirtobrutinib
 - d. Zanubrutinib
10. Which of the following statements best describes the cytokine release syndrome (CRS) observed with epcoritamab in the EPCORE CLL-1 trial for patients with relapsed/refractory chronic lymphocytic leukemia?
- a. CRS was not observed with epcoritamab
 - b. Most events were Grade 1 or 2
 - c. Most events were Grade 3
 - d. Most events were Grade 4